OPKOPKO Health, Inc.Healthcare · Biotechnologyas of 2026-08-13
Horizon

Issued 2026-08-13 at $1.39 · now $1.40 (2026-08-13, +0.7% since)

Based on its own history, a month from the 2026-08-13 close, OPK has typically landed between $1.08 and $1.75 — a range of −22.5% to +25.8% from the issuance price $1.39.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,980 overlapping 1 month windows · 2006-09-262026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.656.0%, ≈1,400 obs).

The cone is anchored at the 2026-08-13 issuance close ($1.39) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where OPK has typically landed a month from the 2026-08-13 close of $1.39 — the range is history, not a prediction.

$1.08worst · -22.5%$1.75best · +25.8%
  • now $1.4 (+0.7%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.37 (-1.4%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.25$1.5
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.08$1.75
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,980 windows spanning 2006-09-26 to 2026-08-13. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2009-02-09−52.8%−52.8%+0.0%
2009-02-11−50.8%−51.6%+2.4%
2009-02-13−48.8%−52.0%+0.0%
3 best
2020-06-19+150.4%+0.0%+150.4%
2007-03-14+128.6%+0.0%+128.6%
2020-06-25+118.3%+0.0%+122.4%

4,980 overlapping windows · 2006-09-262026-08-13 · not cherry-picked

Pending catalysts

  • December 2027Trial primary completion: Phase 1/Phase PHASE2 primary completion: Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
50%
+3.3%
n=20
Feb
45%
+2.7%
n=20
Mar
35%
+2.4%
n=20
Apr
45%
+1.6%
n=20
May
45%
+3.2%
n=20
Jun
55%
+7.7%
n=20
Jul
55%
+5.9%
n=20
Aug
50%
−1.5%
n=20
Sep
37%
−3.6%
n=19
Oct
50%
−0.6%
n=20
Nov
70%
+1.5%
n=20
Dec
35%
−2.3%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.

Last 90 days · as of 2026-08-13 · point-in-time by filing date

No insider transactions on record in the last 90 days.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. Full terms.